Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at Jefferies Group reduced their FY2018 EPS estimates for Vanda Pharmaceuticals in a research note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings of ($0.98) per share for the year, down from their prior forecast of ($0.72). Jefferies Group currently has a “Buy” rating and a $20.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ FY2019 earnings at $0.85 EPS, FY2020 earnings at $0.60 EPS, FY2021 earnings at $1.00 EPS and FY2022 earnings at $2.07 EPS.
Other equities research analysts have also recently issued research reports about the company. Oppenheimer set a $26.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. Piper Jaffray Companies set a $26.00 target price on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 19th. Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Wednesday, October 18th. Seaport Global Securities initiated coverage on Vanda Pharmaceuticals in a research report on Friday, January 19th. They set a “buy” rating and a $20.00 target price for the company. Finally, BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $21.43.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. The company had revenue of $44.28 million for the quarter, compared to the consensus estimate of $44.00 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 EPS.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in Vanda Pharmaceuticals by 2.4% during the fourth quarter. BlackRock Inc. now owns 4,568,159 shares of the biopharmaceutical company’s stock worth $69,436,000 after acquiring an additional 106,228 shares in the last quarter. Vanguard Group Inc. raised its stake in Vanda Pharmaceuticals by 7.5% during the second quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock worth $43,698,000 after acquiring an additional 186,548 shares in the last quarter. Armistice Capital LLC raised its stake in Vanda Pharmaceuticals by 74.8% during the fourth quarter. Armistice Capital LLC now owns 2,678,000 shares of the biopharmaceutical company’s stock worth $40,706,000 after acquiring an additional 1,146,000 shares in the last quarter. Macquarie Group Ltd. raised its stake in Vanda Pharmaceuticals by 20.0% during the fourth quarter. Macquarie Group Ltd. now owns 2,268,691 shares of the biopharmaceutical company’s stock worth $34,484,000 after acquiring an additional 378,606 shares in the last quarter. Finally, State Street Corp raised its stake in Vanda Pharmaceuticals by 2.9% during the second quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock worth $26,380,000 after acquiring an additional 46,299 shares in the last quarter. Institutional investors and hedge funds own 88.19% of the company’s stock.
In related news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the transaction, the insider now directly owns 1,031,848 shares in the company, valued at $15,787,274.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total value of $130,747.68. Following the completion of the transaction, the senior vice president now owns 118,366 shares of the company’s stock, valued at $1,806,265.16. The disclosure for this sale can be found here. Insiders have sold 209,483 shares of company stock valued at $3,205,205 in the last ninety days. Company insiders own 7.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “FY2018 EPS Estimates for Vanda Pharmaceuticals Inc. Lowered by Analyst (VNDA)” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/15/fy2018-eps-estimates-for-vanda-pharmaceuticals-inc-lowered-by-analyst-vnda.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.